Clint Tomlinson
Host
Replay available
Anavex Life Sciences (NASDAQ:AVXL) Q2 2020 earnings call, held 2020-05-07. Watch the replay and read the transcript on 6ix.

On 6ix: 6ix.com/event/anavex-life-sciences-corp-avxl-q2-2020-earnings-call
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:01 Good afternoon. My name is Adrienne, and I'll be your conference call operator today. Welcome to the Anne of X Life Sciences Fiscal 2020 Second Quarter Financial Results Conference Call. As a reminder, this conference call is being recorded. I'd now like to turn the call over to your host for today's conference, Clint Tomlinson. Please go ahead.
0:22 Thank you, and good afternoon, everyone. We appreciate you joining us today for Anne of X Life Sciences Conference Call and Webcast. Our agenda is to review the company's financial results for its second quarter of fiscal 2020 and provide a clinical study update. A taped replay of this call will be available approximately two hours after the call's conclusion and will remain available for one month. The call will also be available for replay on Anavex's website at www.anavex.com. With us today is Dr. Christopher Misling, President and Chief Executive Officer and Sandra Boenisch, Principal Financial Officer. Dr. Misling and Ms. Boenisch will make prepared remarks, and then we will take questions from equity analysts. Before we begin, please note that during this conference call, the company will make some projections and forward-looking statements regarding future events. We encourage you to review the company's filings with the FCC.
1:23 This includes, without limitation, the company's forms 10-K and 10-Q, which identify the specific factors that may cause actual results or events to differ materially from those described in those forward-looking statements. These factors may include, without limitation, risks inherent in the development or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and Maintenance of Intellectual Property Rights. And with that, I'd like to turn the call over to Dr. Misling.
2:04 Thank you. Thank you, everyone, for joining us on today's conference call to review our second quarter financial results and share with you some clinical updates for Anavex 273 or black carmezine. Much has changed around all of us since our last quarterly conference call. As the world navigates COVID-19, Anavex's paramount obligation has always been to ensure the safety of all participants in its clinical programs and the integrity of the studies in which they participate. We are responding to regulatory, institutional, and government guidance in policies related to COVID-19. We remain focused on our clinical development plans and are working closely with all stakeholders to try to mitigate the effect of COVID-19 on companies ongoing clinical trials for Rett syndrome, Parkinson's disease, dementia and Alzheimer's disease. Clinical sites continue to operate and see patients where possible in accordance with local regulations and site policies, regulatory, institutional and government guidance related to COVID-19.
3:15 Clinical sites continue to screen and enroll patients into the active trials and the respective open-label extensions for the two Phase II Rett Syndrome trials and the Phase IIb-3 Alzheimer's disease trial, while the Parkinson's disease dementia Phase II trial has completed enrollment and we expect to announce top-line results from this study by mid-2020. Anavex proactively continues to bring on sites in new countries across programs depending on the situation in each country of operation. While Rett syndrome protocols had always by default allowed at-home visits, US FDA, European EMA, and Australian PGA recommended contingency plans are actively in place for the Alzheimer's Disease Phase II B-3 study and the Parkinson's Disease Dementia Phase II study to ensure remote or virtual assessments for active patients and all respective extension studies.
4:14 Because Anavex 273 is an oral formulation, study participants are able to receive shipments of their study medication in a controlled and compliant fashion, and direct-to-patient delivery is occurring in multiple countries. We understand that some activities will be temporarily slower because of COVID-19. However, our risk mitigation actions were implemented for every project Our primary focus is on the safety of all involved and the continued conduct of our clinical programs as we navigate the pandemic together. Our sites understand why their patients participate in research and are committed to the importance of clinical trials for those patient communities currently without effective treatments. and now I would like to direct the call to Sandra Boenisch, Principal Financial Officer of Annex for a brief financial summary of the recently reported quarter.
5:16 Thank you, Christopher, and good afternoon, everyone. We reported a net loss of 7.2 million or 12 cents per share during the quarter as compared to 7.2 million or 15 cents per share in the comparable quarter of fiscal 2019. Research and development expenses have remained consistent at $6.1 million for the three months ended March 31, 2020. General and administrative expenses have decreased by $0.4 million when compared to the second quarter of 2019 to $1.7 million for the three months ended March 31, 2020. The reduction is primarily related to a reduction in stock option compensation charges. Our cash position at March 31, 2020 was $26.6 million, compared to $22.2 million at September 30, 2019, our fiscal year end.
6:10 Thank you, and now I will turn the call back over to Christopher.
6:14 Thank you, Sandra. In summary, despite these challenging times, we continue to make steady progress towards reaching several important milestones, and we are poised for an exciting time ahead with multiple data readouts. We look forward to providing further updates as advancements continue. I would like now to open the call for questions. Operator, please go ahead. At this time, we'll be conducting a question and answer session for your equity analysis. If you'd like to ask a question, please press star 1 on your telephone keypad. You may press the pound sign or the hash key if you'd like to remove yourself from the queue.
6:59 Standing by for questions. And our first question comes from Rajan Talarju from HC Wainwright. Your line is open.
7:11 Hi, this is Blair Cohen on for ROM. A few questions for you. First, are you concerned in any way about possible data compromise in any of your ongoing trials that are being modified due to COVID-19?
7:25 The advantage of our trial is that there is two questions to assessment by the physician and directly towards the patient and also questions towards the caregiver. And these questions are very the same if you would do it in person or if you would do it over your video or Webex function or over telephone. The other point I like to make that in Parkinson's disease dementia, the assessment is done over a objective computer-based assessment, which is also not dependent on The Interaction or the Interface of the Interaction.
8:23 So I would say that it certainly cannot be excluded that there is an effect of a virtual assessment versus an in-person assessment, but the way these questionnaires and assessments are performed, it would not be differently performed in person or over an interface like video or Webex video or over the telephone.
8:55 Okay, thank you. And what are your thoughts on the recently reported serozotin failure and Rett syndrome in the STARS trial and what implications does this have for Blood Care Magazine, and clearly the competitive landscape.
9:16 So we are obviously aware of this program and it's unfortunate for the patient population. However, we also understand though that this program had a narrower focus on the outcome measures. It was focused on respiration function and not looking at the broader phenotype of Rett syndrome which includes the entire behavioral scale like hand movement overall. physical agility as well as seizures and sleep paradigm and other behaviors interactions so we are not directly affected by this and it shows that this is an unmet need and we continue only to and the rest of our program in order to hopefully be able to provide an improvement for this population.
10:31 Perfect. Thank you.
10:33 What would you consider a slam dunk result from the Phase II trial in Parkinson's dementia? And would you plan to hold an end of Phase II meeting with the FDA on the basis of this data, assuming success?
10:47 So the answer to the last question is we would obviously hold a meeting depending on outcome. And regarding the first question, I would rather like to have the data speak for itself since we don't have any preconceived outcome expectation. This is the very first study in Parkinson's disease dementia with our drug, so it's hard for us to formulate any scenario. Okay, perfect. That's it for me. Thank you. Thank you. If you'd like to remove yourself from the queue, please press the pound sign or the hash key. To ask a question, please press star then 1 on your touch-tone phone.
11:51 And our next question is from Tom Bishop from BI Research.
11:56 Hi, Chris. Hello. At last report, the company indicated it hoped to add a number of sites, like going from 15 to 45. And I was just wondering, and presumably outside of Australia, and I was just wondering how that was going in this environment. I heard you mentioned Europe, I thought, at one point.
12:17 That's right, Europe and North America. And that is the plan. And we are ramping up. We are actually in the process of executing and adding sites. We are obviously also aware, though, that these countries have been affected by COVID in respective ways. Nevertheless, the regulatory process of approving a study seems to be not affected by that. We don't have any delay at this moment, but we will find out if in several months or in the next quarter, when we received approval in the respective countries, How the situation will evolve in regards to each countries in Europe and North America, how they basically will be able to address clinical visits At the same time, because we learned from the situation, we already included in these protocol submissions this ability of doing visits, virtual visits, as well as home visits. for the patients, so we can still be able to move in a parallel trajectory in this alternative scenario. If so, the stay home situation
13:52 gets expanded in Europe or North America. So we believe we've done everything possible to de-risk this situation, and also nobody can anticipate and see what will happen regarding to COVID in the future.
14:13 Okay, so I would take it then that you haven't actually opened any additional sites yet, but you're working full steam on it.
14:22 That's exactly right, yes.
14:24 Okay, so meanwhile, I know last time you said you had gotten to 50%, and this time you said pretty much still 50% plus. Does that mean there haven't been a whole lot of enrollments in this pandemic climate, or are you just kind of going to say 50% until you get to 100%, 50% plus? Yeah.
14:50 Yeah, if I might comment to this, we announced 50% enrollment for the Alzheimer's study for the Phase 2B-3. So we are now today way beyond 50%. What we announced today was that the two Rett Syndrome studies, have also so passed and are beyond, I want to point that out, are beyond 50%. So that is basically two different or three different studies. So they should not be mixed up.
15:21 Is there also a third wet trial that has not yet begun or...
15:25 That's right, so the rectodrome study RS003 where we have been getting approval to start, we have made some additional amendments and for that reason the first patient has not yet initiated, but this is forthcoming as we speak.
15:47 Okay, and from time to time I get a subscriber that says that, you know, he's He's concerned that there hasn't been any insider buying. And I've told him, well, you guys often know too much. And maybe it wouldn't be a good idea to buy or you're in a quiet period anyway. And there's not that many insiders. But could you comment to that? Because I get the question a fair amount.
16:16 So I have shown personally to be active in buying on the open market in the past. and I would not interpret non-buying as is a signal one way or the other. And as you said, it's also not possible to speak about it. And I can't even say that we can speculate this, that there are moments where you cannot buy anymore because you know certain things. So I would not bring this to the forefront. I would just leave it like that. We are very excited about all our programs The Alzheimer's Study, it's very exciting that we're moving forward and we're rolling very nicely actually in Australia. The Parkinson's Disease Study because it's really around the corner and it's going to be data announced very soon.
17:09 And the two RET studies and the third RET study starting soon as well. We're very excited about all our programs. and also like to mention that the Analex 371 study, which we had announced that we plan also for moving into phase one, this is also something we are looking forward to this year.
17:33 Okay, and one last question on the financial side. I saw something about, well, I know you have a deal with Lincoln Park and kind of ATM, and then there's Cantor Fitzgerald, and now I see Lear Inc., and I'm a little confused if those are two different programs or if they're basically all programs that you're using to stay funded.
17:56 So the major contribution for funding was in the past the Lincoln Park, we call it a purchase agreement where we are able from time to time if we like the stock price levels and our burn rate is not so big and our volume is very easily able to absorb that. to just are able to keep the cash position relatively constant over quarter over quarter, as you can see. The ATM with Camptor Fitzgerald, we're very excited that we were able to add now to this agreement, Learing, and that is basically just an amendment of the existing program with Kantor to add leering. It's not a different program.
18:47 It's exactly the same. We're just adding a leering to this program, to this 18 program, which we have not used yet and we regard this program as a safety net if we are not able to find alternatives to fund, but we have not used this program.
19:07 Now, at Lincoln Park, that isn't also an ATM at the market?
19:12 It's called purchase agreement. It has a different name, but the principle is the same. We are selling some shares, and Lincoln Park has to buy it, and we get the money
19:26 in return. Right, but it's pretty much the same thing with Cantor and Learing, but you just have a number of options all ongoing at once?
19:35 That's exactly right. It increases the ability of being able to access capital. That's what is just common good fiscal responsibility to be able not to be put under pressure or being limited in the option to be able to access capital since you know that as a biotech company you don't have revenues and if you don't have revenues you don't have and many more.
20:09 And what was the burn rate? You mentioned that, but I didn't hear anybody say what it
20:12 was. We've been in the past very much in the range of $1 million to $1.5 million, and we're pretty much maybe a little bit higher the last two quarters in this range of $1.5 million to $1.7 million, $1.8 million a month of burn rate.
20:34 Per month?
20:35 Per month, yes.
20:37 Per month, yes, okay. All right, well, thank you very much. And by the way, I'm excited about these programs, too.
20:45 Thank you very much. And our next question comes from Jason Colbert from Dobson James. Your line is open. Hi, this is Alex for Jason. and I think you did a good job talking about how you guys are dealing with COVID-19 and how that's affecting you. But I think it would be great if you can go into more detail about the catalyst and the upcoming quarters for you guys.
21:14 So the upcoming quarter will be an announcement of top line data of the Phase 2 Parkinson's disease dementia study. That is really something we can put on everybody's calendar because the trial has been enrolled the last patient and we now have to wait for the 14 days, 14 weeks, which is the duration of the study, plus the times needed to for the independent Research CRO to build the results, and then we will update the data in a public announcement, the top line data, which will be mid of 2020.
21:59 And we will update the other studies, the Rett Syndrome studies, We will update the enrollment completion and then it's also relatively easy then to predict the expected top line data period of time given that we know how long the trial duration is plus some time needed for the calculation. Well, that's all I had for you, so thank you. Thank you. And that concludes today's question and answer session. I'll turn the call back over to Christopher.
22:38 Thank you all for participating in today's conference call. Should you need additional information or have any other questions, please visit our website at www.anavex.com or call or email us. This concludes our remarks for today. Operator, Thank you ladies and gentlemen. This concludes our call today. You may now disconnect.
Follow Anavex Life Sciences Corp. into a list and get an email when it puts out news.
Host
Equity Analyst
President and Chief Executive Officer
Equity Analyst
Analyst, BI Research
Principal Financial Officer